Literature DB >> 33859467

Impact of an Oral Antineoplastic Renewal Clinic on Medication Possession Ratio and Cost-Savings.

Brooke S Crawford1, Alison L Stauder1, Susan M Bullington1, Patrick J Kiel1, Erin R Dark1, Jill M Johnson1, Alan J Zillich1.   

Abstract

PURPOSE: The primary objective of this study was to evaluate the impact of a pharmacist-driven oral antineoplastic (OAN) renewal clinic on medication adherence and cost savings.
METHODS: This was a preimplementation and postimplementation retrospective cohort evaluation within a single US Department of Veterans Affairs health care system following implementation of a pharmacist-managed OAN refill clinic. The primary outcome was medication adherence defined as the median medication possession ratio (MPR) before and after implementation of the clinic. Secondary outcomes included the proportion of patients who were adherent from pre- to postimplementation and estimated cost-savings of this clinic. Patients were eligible for inclusion if they had received at least 2 prescriptions of the most commonly prescribed oral antineoplastic agents at the institution between September 1, 2013 and January 31, 2015.
RESULTS: Of preimplementation patients, 96 of 99 (96.9%) were male and all patients (n = 35) in the postimplementation group were male. The mean age of the preimplementation group was 69.2 years while the postimplementation group was 68.4 years. Median MPR in the preimplementation group was 0.94, compared with 1.06 in the postimplementation group (P < .001). Thirty-six (36.7%) patients in the preimplementation group were considered nonadherent to their OAN regimen compared with zero patients in the postimplementation group. Estimated total cost savings was $36,335 in the postimplementation period.
CONCLUSIONS: Implementation of a pharmacist-driven OAN renewal clinic was associated with a 12% increase in median MPR while saving an estimated $36,335 during the 5-month postimplementation period.
Copyright © 2021 Frontline Medical Communications Inc., Parsippany, NJ, USA.

Entities:  

Year:  2021        PMID: 33859467      PMCID: PMC8040961          DOI: 10.12788/fp.0107

Source DB:  PubMed          Journal:  Fed Pract        ISSN: 1078-4497


  10 in total

1.  Physician-pharmacist collaboration for oral chemotherapy monitoring: Insights from an academic genitourinary oncology practice.

Authors:  Lisa M Holle; Sonam Puri; Jessica M Clement
Journal:  J Oncol Pharm Pract       Date:  2015-04-21       Impact factor: 1.809

2.  Improved Adherence Rates and Clinical Outcomes of an Integrated, Closed-Loop, Pharmacist-Led Oral Chemotherapy Management Program.

Authors:  Benyam Muluneh; Molly Schneider; Aimee Faso; Lindsey Amerine; Rowell Daniels; Brett Crisp; John Valgus; Scott Savage
Journal:  J Oncol Pract       Date:  2018-05-25       Impact factor: 3.840

Review 3.  NCCN Task Force Report: Oral chemotherapy.

Authors:  Saul N Weingart; Elizabeth Brown; Peter B Bach; Kirby Eng; Shirley A Johnson; Timothy M Kuzel; Terry S Langbaum; R Donald Leedy; Raymond J Muller; Lee N Newcomer; Susan O'Brien; Denise Reinke; Mark Rubino; Leonard Saltz; Ronald S Walters
Journal:  J Natl Compr Canc Netw       Date:  2008-03       Impact factor: 11.908

4.  Health care professional development: Working as a team to improve patient care.

Authors:  Amir Babiker; Maha El Husseini; Abdurrahman Al Nemri; Abdurrahman Al Frayh; Nasir Al Juryyan; Mohamed O Faki; Asaad Assiri; Muslim Al Saadi; Farheen Shaikh; Fahad Al Zamil
Journal:  Sudan J Paediatr       Date:  2014

5.  Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib.

Authors:  David Marin; Alexandra Bazeos; Francois-Xavier Mahon; Lina Eliasson; Dragana Milojkovic; Marco Bua; Jane F Apperley; Richard Szydlo; Ritti Desai; Kasia Kozlowski; Christos Paliompeis; Victoria Latham; Letizia Foroni; Mathieu Molimard; Alistair Reid; Katy Rezvani; Hugues de Lavallade; Cristina Guallar; John Goldman; Jamshid S Khorashad
Journal:  J Clin Oncol       Date:  2010-04-12       Impact factor: 44.544

6.  Evaluation of an outpatient pharmacy clinical services program on adherence and clinical outcomes among patients with diabetes and/or coronary artery disease.

Authors:  Michele M Spence; Abir F Makarem; Stacie L Reyes; Lisa L Rosa; Courtney Nguyen; Elizabeth A Oyekan; Alan T Kiyohara
Journal:  J Manag Care Spec Pharm       Date:  2014-10

7.  Nonadherence to imatinib adversely affects event free survival in chronic phase chronic myeloid leukemia.

Authors:  Prasanth Ganesan; Tenali Gnana Sagar; Biswajit Dubashi; Rejiv Rajendranath; Krishnarathinam Kannan; Sanju Cyriac; Manjunath Nandennavar
Journal:  Am J Hematol       Date:  2011-04-27       Impact factor: 10.047

8.  Medication adherence among adults prescribed imatinib, dasatinib, or nilotinib for the treatment of chronic myeloid leukemia.

Authors:  Kristin R Anderson; Carole R Chambers; Nadine Lam; Patrick S Yau; Frances Cusano; M Lynn Savoie; Naureen Sheikh
Journal:  J Oncol Pharm Pract       Date:  2014-02-06       Impact factor: 1.809

9.  Cohort study examining tamoxifen adherence and its relationship to mortality in women with breast cancer.

Authors:  C McCowan; J Shearer; P T Donnan; J A Dewar; M Crilly; A M Thompson; T P Fahey
Journal:  Br J Cancer       Date:  2008-11-04       Impact factor: 7.640

10.  Prescription refill, patient self-report and physician report in assessing adherence to oral endocrine therapy in early breast cancer patients: a retrospective cohort study in Catalonia, Spain.

Authors:  R Font; J A Espinas; M Gil-Gil; A Barnadas; B Ojeda; I Tusquets; M A Segui; M Margelí; A Arcusa; A Prat; M Garcia; J M Borras
Journal:  Br J Cancer       Date:  2012-09-06       Impact factor: 7.640

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.